EA
OCUL icon

Emerald Advisers’s Ocular Therapeutix OCUL Stock Holding History

Emerald Advisers’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,768
Closed -$176K – 256
2026
Q1 		$176K Hold
20,768
– – 0.01% 217
2025
Q4 		$252K Hold
20,768
– – 0.01% 207
2025
Q3 		$243K Hold
20,768
– – 0.01% 219
2025
Q2 		$193K Hold
20,768
– – 0.01% 220
2025
Q1 		$152K Hold
20,768
– – 0.01% 216
2024
Q4 		$177K Hold
20,768
– – 0.01% 221
2024
Q3 		$181K Hold
20,768
– – 0.01% 218
2024
Q2 		$142K Hold
20,768
– – 0.01% 224
2024
Q1 		$189K Hold
20,768
– – 0.01% 224
2023
Q4 		$92.6K Hold
20,768
– – ﹤0.01% 225
2023
Q3 		$65.2K Sell
20,768
-24,949
-55% -$102K ﹤0.01% 215
2023
Q2 		$236K Hold
45,717
– – 0.01% 205
2023
Q1 		$241K Sell
45,717
-919,524
-95% -$4.37M 0.01% 203
2022
Q4 		$2.71M Sell
965,241
-541,215
-36% -$1.79M 0.13% 113
2022
Q3 		$6.25M Buy
1,506,456
+40,754
+3% +$205K 0.32% 101
2022
Q2 		$5.89M Buy
1,465,702
+173,797
+13% +$657K 0.3% 103
2022
Q1 		$6.39M Buy
1,291,905
+234,178
+22% +$1.3M 0.24% 109
2021
Q4 		$7.37M Buy
1,057,727
+208,127
+24% +$1.62M 0.27% 108
2021
Q3 		$8.5M Sell
849,600
-373,900
-31% -$4.2M 0.31% 104
2021
Q2 		$17.3M Sell
1,223,500
-71,350
-6% -$1.08M 0.63% 72
2021
Q1 		$21.2M Buy
1,294,850
+104,147
+9% +$2.01M 0.77% 53
2020
Q4 		$24.6M Buy
+1,190,703
New +$17.7M 0.82% 48

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Emerald Advisers's OCUL Position: Q2 2026 in Review

Emerald Advisers sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 20,768 shares — an estimated $176K sold.

Emerald Advisers first reported a position in OCUL in Q4 2020 and held it in 22 quarters. The position peaked at $24.6M in Q4 2020. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Emerald Advisers reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Emerald Advisers sold 20,768 Ocular Therapeutix shares in Q2 2026, an estimated $176K.
  • Emerald Advisers first reported a position in Ocular Therapeutix in Q4 2020 and held it in 22 quarters.
  • Emerald Advisers's Ocular Therapeutix position peaked at $24.6M in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.